Advertisement

Annals of Hematology

, Volume 98, Issue 10, pp 2447–2450 | Cite as

Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone

  • Shih-Hsin Liang
  • Su-Peng YehEmail author
Letter to the Editor
  • 85 Downloads

Dear Editor,

A new disease entity, TEMPI syndrome, characterized by the combination of telangiectasia, erythrocytosis and elevated serum erythropoietin level, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting, is included in the 2016 revised World Health Organization classification of tumors of hematopoietic and lymphoid tissues [1]. It is hypothesized to be a result of abnormal plasma cell clones; however, its exact mechanism is unknown. Patients with TEMPI syndrome frequently suffer from distressing symptoms, and management is difficult since the standard treatment is yet to be elucidated. Herein, we report a case of a patient with TEMPI syndrome, who presented with severe fluid accumulation bilaterally in the perinephric space and polycythemia at the time of IgA-kappa multiple myeloma relapsed, and responded dramatically to lenalidomide and dexamethasone.

A 46-year-old non-smoking male was diagnosed about two and a half years ago with multiple...

Notes

Acknowledgments

All authors would like to acknowledge the Division of Hematology and Oncology, Department of Internal Medicine, and China Medical University Hospital for its support while providing a valuable contribution to the work.

Authors’ contributions

SHL carried out the data gathering and drafted the manuscript. SPY provided the concept and data analysis. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Swerdlow S et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, FranceGoogle Scholar
  2. 2.
    Sykes DB, Schroyens W, O'Connell C (2011) The TEMPI syndrome — a novel multisystem disease. N Engl J Med 365(5):475–477CrossRefGoogle Scholar
  3. 3.
    Schroyens W, O'Connell C, Sykes DB (2012) Complete and partial responses of the TEMPI syndrome to bortezomib. N Engl J Med 367(8):778–780CrossRefGoogle Scholar
  4. 4.
    Sykes DB, Schroyens W (2018) Complete responses in the TEMPI syndrome after treatment with daratumumab. N Engl J Med 378(23):2240–2242CrossRefGoogle Scholar
  5. 5.
    Mohammadi F, Wolverson MK, Bastani B (2012) A new case of TEMPI syndrome. Clin Kidney J 5(6):556–558CrossRefGoogle Scholar
  6. 6.
    Kwok M, Korde N, Landgren O (2012) Bortezomib to treat the TEMPI syndrome. N Engl J Med 366(19):1843–1845CrossRefGoogle Scholar
  7. 7.
    Viglietti D, Sverzut J-M, Peraldi M-N (2011) Perirenal fluid collections and monoclonal gammopathy. Nephrol Dial Transplant 27(1):448–449CrossRefGoogle Scholar
  8. 8.
    Ryden A, Wei K, Rodriguez R, Mahrer T (2013) Too much blood: a case of the newly described TEMPI syndrome. CHEST 144(4):927ACrossRefGoogle Scholar
  9. 9.
    Jasim S, Mahmud G, Bastani B, Fesler M (2014) Subcutaneous bortezomib for treatment of TEMPI syndrome. Clin Lymphoma Myeloma Leuk 14(6):e221–e223CrossRefGoogle Scholar
  10. 10.
    Kenderian SS, Rosado FG, Sykes DB, Hoyer JD, Lacy MQ (2015) Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation. Leukemia 29:2414–2416CrossRefGoogle Scholar
  11. 11.
    Belizaire R, Sykes DB, Chen YBA, Spitzer TR, Makar RS (2015) Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency. Transfusion 55(9):2142–2148CrossRefGoogle Scholar
  12. 12.
    Pascart T, Herbaux C, Lemaire A, Soncin F, Hachulla E, Hatron PY, Terriou L (2016) Coexistence of rheumatoid arthritis and TEMPI syndrome: new insight in microangiogenic-related diseases. Joint Bone Spine 83(5):587–588CrossRefGoogle Scholar
  13. 13.
    Abe D, Nakaseko C, Takeuchi M, Tanaka H, Ohwada C, Sakaida E, Takeda Y, Oda K, Ozawa S, Shimizu N, Masuda S, Cho R, Nishimura M, Misawa S, Kuwabara S, Saito Y (2008) Restrictive usage of monoclonal immunoglobulin λ light chain germline in POEMS syndrome. Blood 112(3):836CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hematology and Oncology, Department of Internal MedicineDalin Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationChiayi CountyTaiwan
  2. 2.Division of Hematology and Oncology, Department of Internal MedicineChina Medical University HospitalTaichungTaiwan

Personalised recommendations